ACXP Stock Overview
A clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Acurx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.15 |
| 52 Week High | US$5.28 |
| 52 Week Low | US$1.00 |
| Beta | -1.72 |
| 11 Month Change | -39.42% |
| 3 Month Change | -48.19% |
| 1 Year Change | -68.02% |
| 33 Year Change | -73.68% |
| 5 Year Change | n/a |
| Change since IPO | -85.49% |
Recent News & Updates
Recent updates
Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely
Aug 11
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Jan 22Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Oct 30Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?
Jul 15Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?
Mar 04Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Nov 16Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering
Jul 25Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
May 13Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Jan 22Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth
Sep 30New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Aug 27Shareholder Returns
| ACXP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.6% | 4.3% | 1.6% |
| 1Y | -68.0% | 18.8% | 32.3% |
Return vs Industry: ACXP underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: ACXP underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| ACXP volatility | |
|---|---|
| ACXP Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACXP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACXP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Dave Luci | www.acurxpharma.com |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. Fundamentals Summary
| ACXP fundamental statistics | |
|---|---|
| Market cap | US$19.26m |
| Earnings (TTM) | -US$16.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs ACXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACXP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.44m |
| Earnings | -US$16.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACXP perform over the long term?
See historical performance and comparison